Phase Ⅰ Study of EGFR Targeted TGFβR-KO CAR T Cells in the Treatment of Previously Treated Advanced EGFR-positive Solid Tumors is a PHASE1 clinical asset sponsored by Chinese PLA General Hospital in Solid Tumor, Adult, EGFR Overexpression. SEO and diligence focus: TGFβR-KO CAR-EGFR T Cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.